pharma · Non-small Cell Lung Cancer · Epilepsy
Eisai
Eisai Co.,
Eisai trial registry — 23 ClinicalTrials.gov studies with program phase, status, and indication context.
Tokyo, Japan, JP HQ
41 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Tokyo, Japan, JP
- Employees
- 41
- Programs
- 22
- Drugs
- 31
- Patents
- 0
Eisai clinical trials
Registry index of 23 ClinicalTrials.gov studies linked to Eisai programs — each row shows trial ID, program name, phase, status, and indication.
Eisai trial registry — 23 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Eisai.
-
MORAb-202-G000-201 — Phase 2
Clinical update -
E7386-J081-102 — Phase 2
Clinical update -
E7386-G000-201 — Phase 2
Clinical update -
E2007-G000-236 — Phase 2
Clinical update -
BB-1701-G000-205 — Phase 2
Clinical update -
Zonisamide — Phase 3
Clinical update -
Tazemetostat — Phase 2
Clinical update -
perampanel — Phase 3
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ - 2023-506868-14-00CTIS ↗
MORAb-202-G000-201
Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).
-
CTIS ↗ - 2023-510275-64-00CTIS ↗
E7386-J081-102
Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor
- 2024-510887-22-00CTIS ↗
Lecanemab
Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.
- 2024-510888-39-00CTIS ↗
LECANEMAB
Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗